Illumina Inc. is planning to move next-generation sequencing (NGS) into new markets by expanding its offerings in reproductive health and through the launch of leukocyte antigen typing product in mid-2014 for laboratories seeking next-generation sequencing. It will also continue to work in collaboration with the oncology community to develop test guidelines and infrastructure to build actionable cancer genomics solutions.